All treatments
Treatment
KIOVIG 100 mg/ml solution for infusion clinical trials
2 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Controlled, Open-label, Group-Sequential, Phase 3 Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving B-Cell Maturation Antigen×CD3–Directed Bispecific Antibody Therapy
This study is looking at a medicine called Gammagard Liquid, which helps protect against infections in adults with a type of blood cancer called multiple myeloma. These patients are also receiving another new treatment. Researchers want to see if Gammagard Liquid is better at preventing serious infections from happening in the first place.
For: Primary infection prophylaxis for secondary immunodeficiency (SID) in patients with multiple myeloma (MM) receiving B cell maturation antigen (BCMA)-directed bispecific (BsAb) therapyHungary · Germany · Greece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Influencing Progression of Airway Disease in Primary Antibody Deficiency
This study looks at people with primary antibody deficiency to see if a higher dose of immunoglobulin (Ig) replacement therapy can slow down lung problems. We'll compare lung changes over two years using scans and other health measures. This could help improve treatment for these conditions.
Netherlands